Presentation is loading. Please wait.

Presentation is loading. Please wait.

AXL is not expressed in human prostate tumors.

Published byAri Väänänen Modified over 5 years ago

Similar presentations

Presentation on theme: "AXL is not expressed in human prostate tumors."— Presentation transcript:

1 AXL is not expressed in human prostate tumors.
AXL is not expressed in human prostate tumors. A, AXL expression in prostate cancer patients who did and did not experience a biochemical recurrence (n = 1,405 patients, GenomeDx GRID data set). P value was calculated using the Wilcoxon rank test. B, Recurrence-free survival of patients with high (above the median) and low (below the median) AXL expression (n = 571 patients, Taylor et al. 2010; visualized and analyzed with Project Betastasis). C, Representative images of AXL IHC staining of a prostate tissue microarray; LN, lymph node. C42B cells served as a negative control and DU145 as a positive control. All images at original magnification ×200. D, AXL IHC staining in metastatic patient tissue; top: scale bar, 100 μm; bottom: scale bar, 50 μm. Haley D. Axelrod et al. Mol Cancer Res 2019;17: ©2019 by American Association for Cancer Research

Download ppt "AXL is not expressed in human prostate tumors."

Similar presentations

Histogenic analysis confirms prostate cancer metastasis to lung.

Histogenic analysis confirms prostate cancer metastasis to lung.
25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.
PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.

PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.
BRD4 is associated with poor patient survival and constitutes a promising target for NRASMut melanoma BRD4 is associated with poor patient survival and.

BRD4 is associated with poor patient survival and constitutes a promising target for NRASMut melanoma BRD4 is associated with poor patient survival and.
Geographic distribution in situ of MSI and MSS colorectal cancer–infiltrating lymphocytes. Geographic distribution in situ of MSI and MSS colorectal cancer–infiltrating.

Geographic distribution in situ of MSI and MSS colorectal cancer–infiltrating lymphocytes. Geographic distribution in situ of MSI and MSS colorectal cancer–infiltrating.
IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).
Expression of CD36 and psap in a TMA of human ovarian cancer patients

Expression of CD36 and psap in a TMA of human ovarian cancer patients
Figure S2 Supplementary data a b CCA1 CCA2 CCA4 CCA3 CCA5 EGFR HER2

Figure S2 Supplementary data a b CCA1 CCA2 CCA4 CCA3 CCA5 EGFR HER2
Tregs and APC subsets in TDLNs of patients with cervical cancer.

Tregs and APC subsets in TDLNs of patients with cervical cancer.
PD-1 expression on HCC-infiltrating B cells and its clinical significance. PD-1 expression on HCC-infiltrating B cells and its clinical significance. A–H,

PD-1 expression on HCC-infiltrating B cells and its clinical significance. PD-1 expression on HCC-infiltrating B cells and its clinical significance. A–H,
BRD4 is associated with poor patient survival and constitutes a promising target for NRASMut melanoma BRD4 is associated with poor patient survival and.

BRD4 is associated with poor patient survival and constitutes a promising target for NRASMut melanoma BRD4 is associated with poor patient survival and.
NICD1 immunohistochemical staining in normal and tumor tissue.

NICD1 immunohistochemical staining in normal and tumor tissue.
Quantification of MHC-I, β2m, and T-cell subsets.

Quantification of MHC-I, β2m, and T-cell subsets.
SIRT1 is downregulated in human gastric cancer (GC).

SIRT1 is downregulated in human gastric cancer (GC).
Metformin and rapamycin decreased tumor weights in obese prediabetic mice. Metformin and rapamycin decreased tumor weights in obese prediabetic mice. A:

Metformin and rapamycin decreased tumor weights in obese prediabetic mice. Metformin and rapamycin decreased tumor weights in obese prediabetic mice. A:
TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor tissues. TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor.

TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor tissues. TFAP2A is highly expressed in nasopharyngeal carcinoma cells and tumor.
Immunohistochemical analyses of SHH expression levels in nonmalignant prostate and adenocarcinoma tissues. Immunohistochemical analyses of SHH expression.

Immunohistochemical analyses of SHH expression levels in nonmalignant prostate and adenocarcinoma tissues. Immunohistochemical analyses of SHH expression.
Autophagy restrains pancreatic inflammation and expression of pTBK1, CCL5, and PD-L1 in vivo. Autophagy restrains pancreatic inflammation and expression.

Autophagy restrains pancreatic inflammation and expression of pTBK1, CCL5, and PD-L1 in vivo. Autophagy restrains pancreatic inflammation and expression.
Expression analysis of IGFBP-3 using human whole-genome microarray.

Expression analysis of IGFBP-3 using human whole-genome microarray.
Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

Similar presentations

Ads by Google